Quarterly report pursuant to Section 13 or 15(d)

10. SEGMENTS

v3.19.1
10. SEGMENTS
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
10. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment consists of one and three FDA-licensed source plasma collection facility located in Georgia for the three months ended March 31, 2019 and 2018, respectively. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables: 

 

Three Months Ended March 31, 2019
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ 1,343,983     $ 2,148,898     $ 35,708     $ 3,528,589  
                                 
Cost of product revenue     7,940,346       1,464,833       —         9,405,179  
                                 
(Loss) income from operations     (10,620,807 )     29,579       (2,617,188 )     (13,208,416 )
                                 
Interest and other (expense) income, net     (169,613 )     13,620       (1,268,472 )     (1,424,465 )
                                 
Gain on transfer of plasma center assets     —         11,527,421       —         11,527,421  
                                 
Loss on extinguishment of debt     —         —         (9,962,495 )     (9,962,495 )
                                 
Net (loss) income     (10,790,420 )     11,570,620       (13,848,155 )     (13,067,955 )
                                 
Capital expenditures     110,453       —         —         110,453  
                                 
Depreciation and amortization expense     687,393       114,241       3,696       805,330  
                                 
Total assets     57,529,070       4,038,367       16,552,533       78,119,970  

 

Three Months Ended March 31, 2018
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ 1,666,243     $ 2,340,055     $ 35,708     $ 4,042,006  
                                 
Cost of product revenue     10,697,642       1,545,106       —         12,242,748  
                                 
Loss from operations     (12,724,718 )     (1,038,824 )     (2,768,961 )     (16,532,503 )
                                 
Interest and other expense, net     (240,054 )     (435 )     (1,049,150 )     (1,289,639 )
                                 
Net loss     (12,964,772 )     (1,039,259 )     (3,818,111 )     (17,822,142 )
                                 
Total assets     47,481,781       27,532,613       16,123,231       91,137,625  
                                 
Depreciation and amortization expense     631,832       188,914       8,795       829,541  
                                 
Capital expenditures     105,199       444,047       —         549,246